Dow Jones
30.967,82 -129,44 (-0,42%) Nasdaq
11.322,37 +194,52 (+1,75%) Nikkei 225
26.137,45 -286,02 (-1,08%) EUR/USD
1,0255 -0,0015 (-0,1436%) BTC-EUR
19.606,15 -309,18 (-1,55%) CMC Crypto 200
441,11 +1,09 (+0,25%)
Emergent BioSolutions Inc. (0IGA.L)
| Chiusura precedente | 32,14 |
| Aperto | 31,05 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 30,69 - 31,05 |
| Intervallo di 52 settimane | 30,69 - 31,05 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 2,279B |
| Beta (5 anni mensile) | 0,88 |
| Rapporto PE (ttm) | 12,33 |
| EPS (ttm) | 4,18 |
| Prossima data utili | 27 apr 2022 - 02 mag 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
GAITHERSBURG, Md., June 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted). AV7909 is the company’s new anthrax vaccine candidate evaluated for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conju
- GlobeNewswire
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
GAITHERSBURG, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that two-year persistence data from its phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate were published in The Lancet Infectious Diseases. The article, Safety and immunogenicity of PXVX0317, an aluminum hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised
- GlobeNewswire
Emergent BioSolutions to Participate in Investor Conferences
GAITHERSBURG, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences: Benchmark Healthcare House Call Virtual 1X1 ConferenceJune 2, 2022 NYSE Healthcare & Technology Virtual Investor Access DayJune 8, 2022 East Coast IDEAS ConferenceJune 22, 2022Pre-recorded presentation will be accessible beginning at 6:00 am EThttps://wsw.com/webcast/threepa37/eb
